meta-analysis published online earlier this month in the American Journal of Cardiology , the authors compared carvedilol, a beta blocker, to other beta-1 selective beta blockers (atenolol, bisoprolol, metprolol & nebivolol) and concluded that carvedilol was better at lowering all-cause mortality in patients suffering from heart failure.Well, in a
The problem with this meta-analysis is that it's a meta-analysis. It's not a direct comparison of each drug to its competitors. This type of drug comparison study is rarely published because it's rarely funded & performed. After all, which pharmaceutical company wants to take the chance that their already cleared & marketed drug will lose to a competitor. So you have to leave it to the government to fund this type of study OR you look at the existing literature and run some tricky statistics.
Will I change my prescribing habits based upon a single study, especially a meta-analysis? Probably not. At least not until we find more of a trend as opposed to a possible fluke. As always, discuss your concerns with your prescribing physician before stopping any medication.